My Profile

Search abstracts

Lewis Sheiner


2019
Stockholm, Sweden



2018
Montreux, Switzerland

2017
Budapest, Hungary

2016
Lisboa, Portugal

2015
Hersonissos, Crete, Greece

2014
Alicante, Spain

2013
Glasgow, Scotland

2012
Venice, Italy

2011
Athens, Greece

2010
Berlin, Germany

2009
St. Petersburg, Russia

2008
Marseille, France

2007
KÝbenhavn, Denmark

2006
Brugge/Bruges, Belgium

2005
Pamplona, Spain

2004
Uppsala, Sweden

2003
Verona, Italy

2002
Paris, France

2001
Basel, Switzerland

2000
Salamanca, Spain

1999
Saintes, France

1998
Wuppertal, Germany

1997
Glasgow, Scotland

1996
Sandwich, UK

1995
Frankfurt, Germany

1994
Greenford, UK

1993
Paris, France

1992
Basel, Switzerland



Printable version

PAGE. Abstracts of the Annual Meeting of the Population Approach Group in Europe.
ISSN 1871-6032

Reference:
PAGE 14 (2005) Abstr 766 [www.page-meeting.org/?abstract=766]


poster


Thorsten Lehr Evaluation of an enterohepatic circulation model: predicting the influence of cholestyramine on the pharmacokinetics of meloxicam

T. Lehr (1), C. Tillmann (2), A. Staab (2), H.G. Schaefer (2), C. Kloft (1)

(1) Dept. Clinical Pharmacy, Institute of Pharmacy, Freie Universitaet Berlin, Berlin, Germany (2) Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach a.d.R., Germany

PDF of poster

Objectives & Background: Concentration-time profiles of drugs undergoing enterohepatic circulation (EHC) are often associated with multiple peak phenomena and a longer apparent half-life. Basic models describing EHC were reported in the literature [1]. Lehr et al. developed an EHC model considering the clock time as a control variable for the gall bladder emptying [2]. The objective of this study was to apply and evaluate the model by using data of a drug undergoing EHC (meloxicam [3]). Evaluation was to be performed by a) fitting the model to observed meloxicam plasma concentrations and b) by predicting the effect of interrupting the EHC on pharmacokinetics by co-administration of cholestyramine.

Methods: Plasma concentration-time profiles of 12 subjects treated with 30 mg meloxicam †intravenously (bolus) either alone or concomitantly treated with 4 g t.i.d cholestyramine for four days were analysed. A three compartment model (central, peripheral and bile) with first order elimination was used to describe the data. The release of the bile compartment was controlled by a sine function model, switching the bile compartment periodically on and off. Interruption of EHC was mimicked by setting the rate transfer constant from bile to central compartment to zero.

Results: The model successfully described the plasma concentration-time profiles of all subjects including the multiple peak phenomena. Clearance and half-life of meloxicam after intravenous administration were determined to be 0.367 L/h and 20.1 h respectively. Simulating the interruption of the EHC resulted in a predicted increased clearance of 0.616 L/h and a shortened half-life of 11.0 h. These model-predicted values are in close agreement with the observed results from the compartmental analysis [3].

Conclusion: EHC of meloxicam could be successfully described by the model proposed by Lehr et al. Interruption of the EHC could be reliably predicted. Slight overestimation of clearance and half-life might be caused by an incomplete interruption of the EHC with cholestyramine.
The model might serve as a tool to describe the pharmacokinetics of drugs undergoing EHC and to assess the impact of interrupting the EHC e.g. by co-medication with cholestyramine or charcoal.

References:
[1] Roberts M. et al., Clin. Pharmacokinet., 41, 751-790
[2] Lehr. et al., PAGE Meeting 2004, www.page-meeting.org
[3] Busch U. et al., Eur. J. Clin. Pharmacol., 48, 269-272, 1995